BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mifsud EJ, Tai CM, Hurt AC. Animal models used to assess influenza antivirals. Expert Opin Drug Discov 2018;13:1131-9. [PMID: 30362841 DOI: 10.1080/17460441.2018.1540586] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Schwab LSU, Londrigan SL, Brooks AG, Hurt AC, Sahu A, Deng YM, Moselen J, Coch C, Zillinger T, Hartmann G, Reading PC. Induction of Interferon-Stimulated Genes Correlates with Reduced Growth of Influenza A Virus in Lungs after RIG-I Agonist Treatment of Ferrets. J Virol 2022;:e0055922. [PMID: 35916513 DOI: 10.1128/jvi.00559-22] [Reference Citation Analysis]
2 Buzitskaya Z, Stosman K, Khairullin B, Kassenov M, Nurpeisova A, Abylai Sansyzbay A, Shurygina AP, Aleksandrov A, Sivak K, Stukova M. A New Intranasal Influenza Vector-Based Vaccine TB/FLU-04L Against Tuberculosis: Preclinical Safety Studies. Drug Res (Stuttg) 2022. [PMID: 35318622 DOI: 10.1055/a-1785-3936] [Reference Citation Analysis]
3 Spruit CM, Nemanichvili N, Okamatsu M, Takematsu H, Boons GJ, de Vries RP. N-Glycolylneuraminic Acid in Animal Models for Human Influenza A Virus. Viruses 2021;13:815. [PMID: 34062844 DOI: 10.3390/v13050815] [Reference Citation Analysis]
4 Edmans M, McNee A, Porter E, Vatzia E, Paudyal B, Martini V, Gubbins S, Francis O, Harley R, Thomas A, Burt R, Morgan S, Fuller A, Sewell A, Charleston B, Bailey M, Tchilian E. Magnitude and Kinetics of T Cell and Antibody Responses During H1N1pdm09 Infection in Inbred Babraham Pigs and Outbred Pigs. Front Immunol 2020;11:604913. [PMID: 33603740 DOI: 10.3389/fimmu.2020.604913] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
5 Pollard BS, BLANCOl JC, Pollard JR. Classical Drug Digitoxin Inhibits Influenza Cytokine Storm, With Implications for Covid-19 Therapy. In Vivo 2020;34:3723-30. [PMID: 33144490 DOI: 10.21873/invivo.12221] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
6 McNee A, Smith TRF, Holzer B, Clark B, Bessell E, Guibinga G, Brown H, Schultheis K, Fisher P, Ramos S, Nunez A, Bernard M, Graham S, Martini V, Chrun T, Xiao Y, Kash JC, Taubenberger JK, Elliott S, Patel A, Beverley P, Rijal P, Weiner DB, Townsend A, Broderick KE, Tchilian E. Establishment of a Pig Influenza Challenge Model for Evaluation of Monoclonal Antibody Delivery Platforms. J Immunol 2020;205:648-60. [PMID: 32591390 DOI: 10.4049/jimmunol.2000429] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
7 Saygili E, Dogan-gurbuz AA, Yesil-celiktas O, Draz MS. 3D bioprinting: A powerful tool to leverage tissue engineering and microbial systems. Bioprinting 2020;18:e00071. [DOI: 10.1016/j.bprint.2019.e00071] [Cited by in Crossref: 14] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
8 Toots M, Yoon JJ, Hart M, Natchus MG, Painter GR, Plemper RK. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res 2020;218:16-28. [PMID: 31945316 DOI: 10.1016/j.trsl.2019.12.002] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
9 Chua SCJH, Tan HQ, Engelberg D, Lim LHK. Alternative Experimental Models for Studying Influenza Proteins, Host-Virus Interactions and Anti-Influenza Drugs. Pharmaceuticals (Basel) 2019;12:E147. [PMID: 31575020 DOI: 10.3390/ph12040147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]